CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed
Drug / intervention
Thalidomidedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00001680
NCT00001680Phase 2Completed
CompareCT.gov

A Pilot Trial of Topical Thalidomide for the Management of Chronic Discoid Lupus Erythematosus

National Cancer Institute (NCI)·interventional·Posted Dec 10, 2002·Updated Mar 4, 2008

In Brief

A Phase 2 clinical trial evaluating Thalidomide for Discoid Lupus Erythematosus. Completed, across 1 site.

Detailed Summary

The purpose of this double-masked, pilot trial is to determine whether 20 percent thalidomide ointment is safe and effective for the treatment of chronic discoid lupus erythematosus (CDLE) when used under an occlusive dressing. Seventeen patients with two similar lesions will have lesions randomized to receive either intervention or placebo therapy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiscoid Lupus Erythematosus
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
1997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 10, 2002
Enrollment StartOct 1, 1997
Study CompletionJul 1, 2001
TodayJul 2, 2026
Posted 23.6 years ago

Interventions

Thalidomidedrug